###### Key messages

What is already known about this subject?
=========================================

-   Clinical studies support the structure-modifying effects of sprifermin, a recombinant human fibroblast growth factor 18, in patients with knee osteoarthritis. The 2-year primary analysis of the phase II FORWARD study demonstrated statistically significant dose-dependent modification of change in cartilage thickness in the total femorotibial joint (TFTJ), medial and lateral femorotibial joints, and central medial and lateral TFTJ subregions with intra-articular sprifermin.

-   MRI is commonly used for measuring cartilage thickness changes in specific femorotibial regions in clinical trials. However, region-specific analysis cannot elucidate whether cartilage loss is reduced, wherever it occurs in an individual joint. Application of location-independent analysis methodology can provide a more sensitive and informative analysis of cartilage loss and thickening independent of the location where it occurs.

What does this study add?
=========================

-   This post-hoc exploratory analysis reports cartilage thickness change based on thinning/thickening scores and ordered values of subregional cartilage thickness change for patients with knee osteoarthritis enrolled in the FORWARD study between baseline and 24-month follow-up. It shows that treatment with sprifermin increases cartilage thickness and reduces cartilage loss. Corresponding results for healthy reference subjects from the Osteoarthritis Initiative were summarised to indirectly compare changes in thinning/thickening scores with FORWARD study patients. This comparison to the reference set indicates that thickening more than doubled, whereas thinning almost reduced to the level of healthy subjects, providing strong support for substantial cartilage modification by sprifermin.

###### Key messages

How might this impact on clinical practice or future developments?
==================================================================

-   There are currently no disease- (or structure-) modifying osteoarthritis drugs (DMOADs) approved for use in Europe or the USA.

-   Primary results from the FORWARD study combined with findings from this post-hoc analysis suggest that sprifermin should be evaluated further in clinical trials as a potential DMOAD therapy for knee osteoarthritis that can substantially reduce cartilage loss.

Introduction {#s1}
============

Osteoarthritis (OA) is characterised by loss of articular cartilage, which is associated with clinical outcomes including knee replacement.[@R1] Whereas current treatments alleviate symptoms without targeting structural progression,[@R3] disease-modifying OA drugs (DMOADs) aim to modify tissue structure, such as articular cartilage, ideally in conjunction with improving clinical outcomes.[@R4] No DMOADs have yet been approved in the USA or Europe.

Clinical studies support the structure-modifying effects of the recombinant human fibroblast growth factor 18, sprifermin, in knee OA.[@R6] The 2-year primary analysis of the phase II FORWARD study demonstrated statistically significant dose-dependent modification of cartilage thickness change by quantitative MRI in the total femorotibial joint (TFTJ), and (central) medial and lateral femorotibial compartments with intra-articular (i.a.) sprifermin.[@R8]

MRI can measure cartilage thickness change in femorotibial subregions.[@R9] Yet, region-specific analysis cannot elucidate whether cartilage loss is reduced wherever it occurs in an individual joint. Location-independent analysis methodology, based on ordering subregional cartilage thickness change, provides a more sensitive and informative analysis of cartilage loss and thickening.[@R9] Location-independent methods were used in a 1-year, placebo-controlled, proof-of-concept phase Ib study,[@R7] which suggested that i.a. sprifermin reduced cartilage loss in addition to increasing cartilage thickness.[@R10] However, this used a small sample size, and the extent to which structure modification affected the cartilage thinning score compared with healthy subjects was not studied.

We conducted a post-hoc, exploratory analysis using thinning/thickening scores and ordered values (OVs) calculated from the larger FORWARD study, to evaluate whether sprifermin reduces cartilage loss independent of location in a given knee, in addition to the dose-dependent increase in mean cartilage thickness in the TFTJ.[@R8] Further, we indirectly compared changes in thinning/thickening scores[@R10] in FORWARD[@R8] with those in healthy reference subjects from the Osteoarthritis Initiative (OAI).[@R13]

Methods {#s2}
=======

FORWARD study design {#s2-1}
--------------------

FORWARD is a multicentre, randomised, double-blind, placebo-controlled, dose-finding, phase II, 5-year study (NCT01919164). Study methods have been reported previously.[@R8] Briefly, patients aged 40--85 with symptomatic radiographic knee OA, Kellgren-Lawrence Grade 2 or 3, and medial minimum joint space width ≥2.5 mm in the target knee were randomised (1:1:1:1:1) to receive three once-weekly i.a. injections of: 30 µg sprifermin every 6 months (q6mo); 30 µg sprifermin every 12 months (q12mo); 100 µg sprifermin q6mo; 100 µg sprifermin q12mo; or placebo. The primary endpoint was change in total TFTJ cartilage thickness from baseline to 2 years, by quantitative MRI. See [online supplementary file 1](#SP1){ref-type="supplementary-material"} for patient involvement information.
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Structural change measurements {#s2-2}
------------------------------

Clinical MRI scanners (1.5/3 Tesla (T)) obtained MRI acquisitions[@R8] for assessing cartilage thickness in 16 femorotibial subregions.[@R16]

Changes in subregional cartilage thickness between baseline and 24 months were ranked by magnitude to create 16 location-independent OVs, as described previously.[@R10] OV1 corresponded to the largest loss/smallest gain and OV16 to the smallest loss/largest gain in cartilage thickness in any subregion within each knee. Thinning and thickening scores for each knee were defined as the sum of each of the 16 subregions with negative and positive changes, respectively.[@R10] To determine the relationship between cartilage loss and gain, the ratio of the thickening to thinning score was calculated for each patient. Mean thinning/thickening scores were informally compared with measurements from an OAI reference group,[@R17] comprising 82 healthy subjects without radiographic knee OA, who were assessed at baseline and 24 months using the same image acquisition and analysis technology[@R16] as in the FORWARD study.[@R8] Healthy reference subjects from the OAI had no knee pain, no radiographic signs of knee OA and no risk factors for knee OA.[@R13]

Statistical analysis {#s2-3}
--------------------

In this exploratory, post-hoc analysis, differences between treatment groups were evaluated using a t-test, without adjusting for multiple comparisons. Patients in the modified intent-to-treat (mITT) population who had baseline and 24-month MRI data (thinning/thickening analysis set) were included. All endpoints were considered exploratory.

Results {#s3}
=======

Patients {#s3-1}
--------

Baseline characteristics for the thinning/thickening score analysis set ([online supplementary table 1](#SP1){ref-type="supplementary-material"}) were similar to those previously reported for the mITT population.[@R8]

Cartilage thinning and thickening scores {#s3-2}
----------------------------------------

Thinning scores were lower for all sprifermin doses versus placebo; statistically significantly less thinning was observed for the highest sprifermin dose (100 µg q6mo; [table 1](#T1){ref-type="table"}). Thinning scores with this dose approached those observed in OAI healthy reference subjects over the same 24-month observation period.

###### 

Mean (95% CI) thinning and thickening scores by FORWARD treatment group (modified intent-to-treat population) and in the Osteoarthritis Initiative healthy reference cohort over 24 months

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Mean\                          Placebo\              Sprifermin            OAI healthy reference cohort (n=82)                                               
  (95% CI)                       (n=83)                                                                                                                        
  ------------------------------ --------------------- --------------------- ------------------------------------- --------------------- --------------------- ---------------------
  Thinning, µm                   −766 (−972 to −560)   −729 (−910 to −548)   −641 (−815 to −467)                   −597 (−777 to −416)   −432 (−521 to −343)   −335 (−381 to −288)

  Difference versus placebo      --                    37 (−234 to 309)      125 (−143 to 393)                     170 (−101 to 441)     334 (114 to 554)\*    --

  Thickening, µm                 431 (358 to 505)      522 (447 to 596)      571 (475 to 666)                      881 (759 to 1003)     856 (717 to 996)      356 (313 to 398)

  Difference versus placebo      --                    90 (−14 to 195)       139 (19 to 259)\*                     450 (305 to 594)\*    425 (267 to 584)\*    --

  TFTJ cartilage thickness, µm   −21 (−36 to −5)       −12 (−26 to 2)        −5 (−20 to 10)                        20 (4 to 37)          29 (15 to 43)         --

  Difference versus placebo      --                    9 (−12 to 30)         16 (−5 to 38)                         41 (18 to 64)\*       50 (30 to 71)\*       --
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*t-test p value\<0.05.

OAI, osteoarthritis initiative; q6mo, every 6-month active cycles; q12mo, every 12-month active cycles; TFTJ, total femorotibial joint.

Thickening scores were substantially greater with sprifermin versus placebo; differences were statistically significant for the 100 µg q6mo, 100 µg q12mo and 30 µg q6mo dose groups. The highest doses (100 µg q6mo and q12mo) of sprifermin approximately doubled the cartilage thickening score compared with placebo and OAI healthy reference subjects ([table 1](#T1){ref-type="table"}).

The thickening:thinning score ratio was 1.06 in OAI healthy reference subjects, indicating no net loss or gain of cartilage. For the sprifermin 100 µg q6mo and q12mo dose groups, the thickening:thinning score ratio was higher than that obtained for the OAI healthy reference subjects (1.98 and 1.48, respectively), indicating cartilage thickness gain. The thickening:thinning score ratio was lower in the placebo group (0.56) versus OAI healthy reference subjects, indicating cartilage thickness loss ([figure 1](#F1){ref-type="fig"}).

![Ratio of thickening:thinning scores by FORWARD treatment group (modified intent-to-treat population) and in the Osteoarthritis Initiative healthy reference cohort over 24 months. q6mo, every 6-month active cycles; q12mo, every 12-month active cycles.](annrheumdis-2019-216453f01){#F1}

OVs and subregion analysis {#s3-3}
--------------------------

Sprifermin-treated patients (100 µg q6mo) gained more and lost less cartilage thickness across OVs versus placebo-treated patients over 24 months; the difference reached statistical significance in all 16 OVs ([figure 2A](#F2){ref-type="fig"}; [online supplementary table 2](#SP2){ref-type="supplementary-material"}). The decrease from baseline was substantially lower in OV1 (the largest loss in cartilage thickness in any subregion within each knee) and the increase substantially greater in OV16 (the largest gain in any subregion within each knee) with sprifermin than placebo.
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![Mean change from baseline (95% CI) in cartilage thickness (μm) over 24 months for (a) 16 OVs and for (b) the 16 subregions in the sprifermin 100 µg q6mo and placebo groups (modified intent-to-treat population). CLF, condyle lateral femur; CMF, condyle medial femur; LT, lateral tibia; MT, medial tibia; OV, ordered value; q6mo, every 6-month active cycle. \*Denotes statistically significant treatment effect: t-test p value\<0.05.](annrheumdis-2019-216453f02){#F2}

Change in cartilage thickness from baseline to 24 months was modified significantly with sprifermin 100 µg versus placebo in 11 of 16 femorotibial subregions. The greatest differences were observed in the central lateral femur and central medial tibia ([figure 2B](#F2){ref-type="fig"}; [online supplementary table 3](#SP3){ref-type="supplementary-material"}).
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Discussion {#s4}
==========

This is the largest study, to date, to apply location-independent analysis of cartilage change in a DMOAD trial, and the first to compare cartilage thinning/thickening scores from treated patients versus healthy reference subjects. Location-independent analysis of thinning and thickening scores demonstrated efficacy with sprifermin over 24 months, whereby sprifermin increased cartilage thickness, and substantially reduced cartilage loss compared with placebo. Thinning scores with sprifermin 100 µg q6mo were approaching those observed in OAI healthy reference subjects, whereas thickening scores were more than doubled.

In a subset of the OAI progression cohort, the greatest per cent change and sensitivity to change in cartilage thickness were observed in the external and central medial tibia, and in the central medial femoral condyle.[@R17] These regions might be assumed to represent high load-bearing regions of the joint and regions with pre-existing cartilage damage. Sprifermin did not appear to be less effective in these subregions than in other subregions in the medial compartment or in the lateral tibia. Indeed, one of the regions with the greatest difference between sprifermin and placebo was the central medial tibia.

Limitations were potential for type 1 error due to multiple comparisons, and use of healthy reference subjects from a different cohort (the OAI[@R13]); consequently, caution must be applied when interpreting the data. However, subjects in the OAI study cohort were of a similar age to the FORWARD population and the studies used the same MR imaging sequences, orientation (coronal), parameters, spatial resolution and analysis technology.[@R18] Additionally, the current analysis did not evaluate the association of the modification of thinning/thickening scores with change in pain and/or inflammation (synovitis). Although a potential limitation, as 1.5 T MRI has a slightly lower signal-to-noise ratio than 3 T, precision errors have been shown to be only marginally greater at 1.5 T, and thickness measures were consistent between 1.5 T and 3 T.[@R19]

Key strengths of this study include the robust design and relatively large sample size of FORWARD, and the comparison of findings with healthy reference subjects. In knee OA, some knees show preferential changes in the medial compartment, while others show greater changes in the lateral compartment.[@R12] Clinical trials often do not account for differences in disease laterality, or restrict observations to those with only medial disease, limiting generalisation to subjects with lateral OA. In contrast, FORWARD intentionally included patients with both medial and lateral disease. In this context, location-independent analysis is particularly advantageous, as it covers cartilage thinning and thickening wherever it occurs in a joint, independent of the compartment and location primarily affected. Thinning/thickening scores and OVs were shown to be sensitive and efficient methods for measuring independent changes in cartilage thickness in either direction.[@R9] In contrast, global or regional cartilage volume or thickness measurements may miss increases or decreases in cartilage thinning or thickening that occur simultaneously in a joint, although in different subregions.[@R11] Furthermore, such measurements cannot be used to discriminate between an increase in cartilage thickening (in some regions) in isolation, or in combination with modification of cartilage thinning at any given position within a joint.[@R9]

The current results support the concept that sprifermin increases cartilage thickness, and reduces cartilage loss. They expand the primary FORWARD results, showing structural modification of cartilage thickness with sprifermin.[@R8] Sprifermin should be evaluated further in clinical trials as a potential DMOAD for knee OA.
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